Korean J Med.  2006 Oct;71(4):426-430.

A case of clopidogrel induced neutropenia

• Kim MW
• Yoon JH
• Kim CH
• Kang HM
• Park JH
• Im JG
• Kim TI

Abstract

Clopidogrel is an oral agent that blocks ADP receptor-mediated platelet aggregation. Clopidogrel along with aspirin was shown by the CURE trial to result in a 20% relative reduction of cardiovascular death, myocardial infarction or stroke. Ticlopidine has been shown to reduce the incidence of stent thrombosis compared with warfarin, but it may cause serious hematological side effects. However, the reported neutropenia has been similar to clopidogrel and aspirin treatment groups (0.01 vs 0.17%, respectively) with corresponding rates (0.05 vs 0.04%, respectively) of severe neutropenia. We treated a 72-year-old female patient with severe neutropenia who underwent percutaneous coronary intervention with drug-eluting stent placement and had no neutrophils in the peripheral blood at 11 days after clopidogrel use. Therefore, clinicians should be alerted to the possibility of severe neutropenia with clopidogrel treatment.

Keyword

Clopidogrel; Neutropenia

MeSH Terms

Adenosine Diphosphate
Aged
Aspirin
Drug-Eluting Stents
Female
Humans
Incidence
Myocardial Infarction
Neutropenia*
Neutrophils
Percutaneous Coronary Intervention
Platelet Aggregation
Stents
Stroke
Thrombosis
Ticlopidine
Warfarin
Adenosine Diphosphate
Aspirin
Ticlopidine
Warfarin